Want to see TSE:HEM full AI Analyst Report?
HEM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.14
Previous CloseN/A
Volume21.00K
Average Volume (3M)138.35K
Market Cap
C$13.85M
Enterprise ValueC$14.32M
Total Cash (Recent Filing)C$319.24K
Total Debt (Recent Filing)C$3.62M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regenerative Medicine FocusHemostemix’s core focus on autologous stem-cell therapies for cardiovascular and ischemic indications aligns with durable structural demand in regenerative medicine. This niche entails high entry barriers, specialized know-how and long development horizons that can create sustainable competitive advantages if clinical programs progress.
Lean Operating StructureA small, focused headcount supports lower fixed overhead and can extend runway relative to larger peers, enabling concentrated R&D spending and faster decision cycles. For pre-revenue biotech, this lean footprint is a durable operational advantage for conserving cash while advancing clinical and manufacturing activities.
Measured Debt BehaviorDespite balance-sheet pressures, management avoided a material debt spike in the most recent period, indicating measured financing choices. Stable debt—rather than abrupt increases—reduces short-term refinancing strain and suggests some discipline in preserving optionality while pursuing clinical milestones.
Bears Say
No Revenue And Widening LossesHemostemix remains a pre-revenue biotech with widening operating losses, signaling a higher cash-burn phase without offsetting commercial traction. Over the next 2–6 months this structural lack of revenue increases dependence on external capital and elevates execution risk for sustaining clinical programs.
Negative Shareholders' Equity & Shrinking AssetsPersistent negative equity and a contracting asset base materially weaken balance-sheet resilience. This structural fragility limits borrowing capacity, reduces collateral for financings and heightens insolvency risk, making the company more vulnerable if clinical timelines slip or capital markets tighten.
Chronic Negative Cash Flow And Rising BurnSustained negative operating and free cash flow, and a recent sharp increase in cash burn, create a structural financing imperative. Ongoing reliance on external funding raises dilution and execution risk, compresses runway, and forces prioritization of programs or cost cuts absent durable cash generation.
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.04 and its highest was C$0.14 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$13.85M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Aug 31, 2026 which is in 17 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 197,796,450 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.